2023 ESMO Congress Research Highlights


Prostate Cancer Updates - GU Oncology Conference Highlights: ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2023.

Kidney Cancer Updates - GU Oncology Conference Highlights: ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.

Dual-Action Drug Produces Positive Results in Patients with Advanced Neuroendocrine Tumors, Trial Finds

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber.

Kidney Cancer Study Shows Improved Outcomes for Patients with Advanced Disease when Treated with Belzutifan over Everolimus

Patients previously treated with immune checkpoint inhibitors and anti-angiogenics showed improved progression free survival with no new safety concerns.